We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Seneca Growth Capital VCT plc (SVCT) B Shares

Sell:54.50p Buy:57.50p 0 Change: No change
Market closed Prices as at close on 22 July 2024 Prices delayed by at least 15 minutes | Switch to live prices |
Sell:54.50p
Buy:57.50p
Change: No change
Market closed Prices as at close on 22 July 2024 Prices delayed by at least 15 minutes | Switch to live prices |
Sell:54.50p
Buy:57.50p
Change: No change
Market closed Prices as at close on 22 July 2024 Prices delayed by at least 15 minutes | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Objective

The objective of Company is to provide shareholders with an attractive income and capital return by investing its funds in a portfolio of both unquoted and AIM/NEX quoted UK companies which meet the relevant criteria under the VCT Rules. The Company will target well managed businesses with strong leadership, that can demonstrate established and proven concepts, and are seeking an injection of growth capital to support their continued development. At least the minimum required percentage of the assets of Company will be invested in Qualifying Investments as required by the VCT Rules, with the remainder held in cash and money market securities.
Security Weight
Solascure Limited 7.24%
Pro Biotix Health Plc 5.23%
Polarean Imaging Ltd ORD GBP0.00037 4.84%
Arecor Therapeutics plc ORD GBP0.01 4.02%
Fabacus Holdings Limited 3.76%
Qudini Limited 3.34%
Silkfred Limited 3.34%
Old St Labs Limited 3.34%
Aptamer Group Plc 3.05%
Poolbeg Pharma Ord Shares 2.57%

Top 10 sectors currently unavailable.

Country Weight
United Kingdom 16.22%

Fee Structure

Annual management fee of 2% of the weighted NAV of the B share and an annual fee of GBP 9,000 in relation to management accounting services, payable quarterly in arrears. Performance fee of an amount equal to 20% of the shareholder proceeds arising.

Dividend Policy

The Company aims to maintain dividends of at least 3p per annum in relation to the Company’s B shares with an ambition to increase this to c.5% per annum of the B share NAV by 2023. This ambition remains but of course is dependent on a number of factors including investment performance and in particular the performance of the B share pool’s AIM quoted investments.

ASSET SPLIT

Total number of holdings: 20.

Trust Manager

Not currently available for this investment trust.

Manager Bio

Not currently available for this investment trust.

Board Of Directors

Ian DigheChairman, Mary Cordeiro, Richard Manley, Alex Clarkson

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Objective, holding data, trust manager and bio information, dividend policy, asset split and fee structure are provided by Morningstar.

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.